Breaking News
AbbVies Acquisition of ImmunoGen Revolutionizing Cancer Treatment
On February 12, 2024, AbbVie successfully concluded its acquisition of ImmunoGen, marking a significant milestone for both companies. With this...
Anixa Biosciences Initiates Treatment for Second Group in Phase 1 Clinical Trial for Revolutionary CART Therapy Targeting Ovarian Cancer
On February 12, 2024, Anixa Biosciences, a pioneering biotechnology company, commenced treatment for the fourth participant in their groundbreaking Phase...
Positive Restatement of ICU Eyewear Holdings Incs Financial Results for 2021 and 2022
1847 Holdings LLC (NYSE:EFSH), a diversified acquisition holding company, has announced a significant positive restatement of the financial results for...
Revolutionizing XR Experiences The Wearable Devices and Qualcomm Technologies Collaboration
On February 12, 2024, a groundbreaking collaboration was announced between Wearable Devices and Qualcomm Technologies. This partnership marked a pivotal...
Plug Power Unveils HL450DP A Revolutionary Portable Hydrogen Refueling Station
On February 12, 2024, Plug Power unveiled a groundbreaking product known as the HL-450D-P. This remarkable portable hydrogen refueling station...
Citigroup Analyst Reinstates Coverage on Rocket Lab USA with Bullish Outlook
On February 12, 2024, Citigroup analyst Jason Gursky made a significant move by reinstating coverage on Rocket Lab USA (NASDAQ:...
Expansion of Medicare Coverage for Eversense E3 Continuous Glucose Monitoring System
On February 12, 2024, Ascensia Diabetes Care and Senseonics made an exciting announcement regarding the Eversense E3 Continuous Glucose Monitoring...
Tonix Pharmaceuticals Receives FDA Clearance for Phase 2 OASIS Trial of TNX102 SL for Acute Stress Disorders
On February 12, 2024, Tonix Pharmaceuticals received clearance from the FDA for its Investigational New Drug (IND) application regarding the...
Calidi Biotherapeutics Unveils Revolutionary Systemic Enveloped Oncolytic Virotherapy Platform
On February 12, 2024, Calidi Biotherapeutics will unveil groundbreaking details about its revolutionary systemic enveloped oncolytic virotherapy platform, a promising...
Immunovant Reports Impressive Quarterly Performance and Strong Financial Position
On February 12, 2024, Immunovant (NASDAQ: IMVT) unveiled its impressive quarterly performance, surpassing market expectations with a loss per share...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
